R&D Spotlight:
Delivering Therapies Across the Blood-Brain Barrier
Delivering Therapies Across the Blood-Brain Barrier
SPONSORED BY
Discover the latest strategies for overcoming the blood-brain barrier and improving delivery of therapeutics to the central nervous system.
Explore next-generation BBB transport technologies, CNS-targeted therapeutic engineering, nanoparticles and non-viral delivery systems, alongside alternative routes for delivering therapies to the brain. This focused online showcase brings together industry experts to examine practical approaches to advancing CNS drug delivery and overcoming one of the key challenges in neuroscience drug development.
- Overcome BBB Delivery Barriers – Explore next-generation technologies and transport mechanisms designed to improve therapeutic delivery across the blood-brain barrier
- Engineer CNS-Targeted Therapies – Gain insights into designing therapeutics and delivery systems to improve brain exposure and therapeutic potential
- Explore New Delivery Strategies – Examine nanoparticles, non-viral delivery systems and alternative routes for delivering therapies to the brain
VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:
- CNS Drug Development
- Blood-Brain Barrier Research
- Drug Delivery
- Neuropharmacology
- Nanomedicine
- Therapeutic Engineering
- Formulation Development
- Neuroscience
- Translational Medicine
- Therapeutic Delivery
60-Minute Agenda
Industry Presentation
Industry Presentation
Solution Provider Presentation
Panel Discussion
End of Technology Showcase
About 10x Genomics
10x Genomics builds technologies that turn biology into answers, giving researchers the resolution to see how diseases develop and respond to treatment.
Its Chromium Single Cell platform delivers single cell multiomics across thousands of samples and billions of cells, even from FFPE, while its spatial portfolio spans Atera In Situ, Xenium In Situ, and Visium Spatial for whole transcriptome insight at subcellular resolution.
Newer additions like Flex Apex and Atera push sample access and throughput further still, profiling FFPE and fixed whole blood and running up to 800 whole transcriptome samples per year. This work powers breakthroughs across pharma, oncology, immunology, and AI cell models, and has been cited in over 10,000 publications by scientists advancing their research worldwide.
